California is currently home to 5619 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Recruiting
Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: University of California, Irvine Medical Center, Orange, California
Conditions: Colorectal Cancer; Lung Cancer
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Recruiting
Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 3 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, and tolerability of revumenib.
Gender:
ALL
Ages:
30 days and above
Trial Updated:
11/19/2024
Locations: City of Hope Comprehensive Cancer Center, Duarte, California
Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
Combination of TATE and PD-1 Inhibitor in Liver Cancer
Recruiting
This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, advanced hepatocellular carcinoma (HCC),and metastatic gastric cancer. All enrolled patients need to have liver lesions and have progressed on a prior immune checkpoint inhibitor.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/19/2024
Locations: University of California, Irvine, Orange, California
Conditions: Hepatocellular Carcinoma, Gastric Cancer
Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA)
Recruiting
The purpose of the study is to characterize the clinical course of homocystinuria in pediatric and adult patients aged 1 to 65 years under current clinical management practices
Gender:
ALL
Ages:
Between 1 year and 65 years
Trial Updated:
11/19/2024
Locations: Travere Investigational Site - Virtual Site, Culver City, California
Conditions: Homocystinuria Due to CBS Deficiency
Myotonic Dystrophy Family Registry
Recruiting
The Myotonic Dystrophy Family Registry (MDFR) is an online, patient-entered database that collects information on myotonic dystrophy (DM) to aid researchers in developing new, effective treatments and help identify participants for research studies and clinical trials.
Gender:
ALL
Ages:
All
Trial Updated:
11/19/2024
Locations: Myotonic Dystrophy Foundation, Oakland, California
Conditions: Myotonic Dystrophy, Congenital Myotonic Dystrophy, Myotonic Dystrophy 1, Myotonic Dystrophy 2, Dystrophia Myotonica, Dystrophia Myotonica 1, Dystrophia Myotonica 2, Myotonia Dystrophica, Myotonic Dystrophy, Congenital, Myotonic Myopathy, Proximal, PROMM (Proximal Myotonic Myopathy), Proximal Myotonic Myopathy, Steinert Disease, Steinert Myotonic Dystrophy, Steinert's Disease, Myotonia Atrophica
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Recruiting
This phase 1 study is to determine the optimal dose and tolerability of a hypoxia-activating agent, tirapazamine, when it is combined with embolization in liver cancer. Liver cancer patients who are Child-Pugh score A, suitable for embolization with tumor no more than 4 nodules are eligible. Tirapazamine will be given by intra-arterial injection before embolization. Treatment effect is evaluated by MRI based on mRECIST criteria. Repeat treatment is necessary only if disease progression. Dose esc... Read More
Gender:
ALL
Ages:
Between 20 years and 99 years
Trial Updated:
11/19/2024
Locations: Stanford University, Palo Alto, California
Conditions: Hepatocellular Carcinoma, Gastrointestinal Cancer Metastatic, Neuroendocrine Tumors
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
Recruiting
The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives of the Registry are: * To enhance understanding of the variability, progression, identification, and natural... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/19/2024
Locations: Tower Hematology/Oncology Medical Group- Site Number : 840056, Beverly Hills, California
Conditions: Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
Mucopolysaccharidosis I (MPS I) Registry
Recruiting
The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities. The objectives of the Registry are: * To evaluate the lon... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/19/2024
Locations: Southern California Permanente Medical Group- Site Number : 840108, Los Angeles, California
Conditions: Mucopolysaccharidosis I (MPS I)
Transnasal Sphenopalatine Ganglion Block for Treatment of Acute Subarachnoid Hemorrhage Associated Headache
Recruiting
The study titled \"Transnasal sphenopalatine ganglion block for treatment of acute subarachnoid hemorrhage associated headache\" is a randomized controlled pilot study aimed at evaluating the efficacy of a transnasal sphenopalatine ganglion (SPG) block in addition to standard pain medication for reducing headache severity in patients with acute subarachnoid hemorrhage (aSAH). The study also examines whether this intervention can reduce opioid requirements during hospitalization and upon... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
11/18/2024
Locations: UC Davis Medical Center, Sacramento, California
Conditions: SAH (Subarachnoid Hemorrhage), Headache
Developing Tools for Dialysis Decision Support
Recruiting
The aim of this study is to evaluate the impact of a web-based dialysis decision support tool on decisional conflict, and values-treatment concordance and other decisional outcomes in individuals with advanced chronic kidney disease, and to assess the tool's acceptability and usability.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
11/18/2024
Locations: U.S. Department of Veterans Affairs - Palo Alto Health Care System, Palo Alto, California
Conditions: Chronic Kidney Diseases
An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
Recruiting
The purpose of this observational study is to learn about the effects of etrasimod as a treatment for adult patients with moderate to severe ulcerative colitis. Patients will be treated according to standard of care and will only be included in the study if etrasimod is the best treatment of choice according to the physician and they have not previously taken etrasimod. All patients will be prescribed etrasimod according to standard of care. Tests and doctor visits will be conducted according t... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
11/18/2024
Locations: Amicis Research Center, Valencia, California
Conditions: Colitis, Ulcerative
Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer
Recruiting
This is an open label, Phase 1, dose escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab in patients with immune checkpoint inhibitor refractory non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2024
Locations: Hoag Memorial Hospital Presbyterian, Newport Beach, California
Conditions: Lung Cancer